During the period from 1960 to 1996, despite improvements in chemotherapy regimens, there was no improvement in the median probability of survival following diagnosis in patients with Low Grade Lymphoma, principally Follicular and Small Cell Lymphoma (the two most common histopathologic forms of Low Grade Non-Hodgkin's Lymphoma). Although therapy can often be delayed in the asymptomatic individual, once symptoms appear and require intervention, the pattern of the so-called "low grade lymphoma paradox" is observed; that is clinical disease relapse despite a good clinical response (seemingly a Complete Response [CR]) for months or years following chemotherapy with a median interval of Progression Fee Survival [PFS] approaching 10 years. Following relapse and re-treatment, the PFS is shorter than after the initial response. With each relapse, the subsequent PFS is shorter and shorter until in one report (prior to the introduction of immunotherapy), the duration of response was approximately 3 months (1). The introduction of immunotherapy using rituximab, a murine derived monoclonal antibody that recognizes the CD20 epitope which is regularly expressed on normal B cells and malignant clones derived from B cells, has improved the duration of PFS. Rituximab promotes apoptosis via several cytotoxic mechanisms. Although initially used following relapse of disease or in patients who had failed to respond to chemotherapeutic regimens, the clinical role of rituximab has progressed to where at the present time, it is now a routine component of most chemotherapeutic regimens. CHOP [Cyclophosphamide-Hydroxydaunorubicin-Oncovin (vincristine)-Prednisone] which had been the most frequent chemotherapeutic combination to treat follicular low grade lymphoma] has been succeeded by CHOP-R in which a course of rituximab infusions follows each cycle of CHOP. CVP has been replaced by CVP-R. Radioimmunotherapy uses an anti-CD 20 antibody to deliver a β-emitting radionuclide to B-cells, thus providing whatever direct cytotoxic effect as a result of immunoglobulin fixation combined with a delivery of a local radiation flux, thus altering the life cycle of cells even if they have not been bound with antibody. As expected, radioimmunotherapy has resulted in further improvement in clinical responses compared to immunotherapy alone.
Zevalin®
This presentation will review the product Zevalin® which is the only commercial product currently available in Europe. Zevalin® is actually a regimen: a combination of the unlabeled anti-CD 20 antibody, rituximab, followed by an infusion of an antibody, is derived. The anti-CD 20 portion is similar in both the rituximab and inbritumomab molecules. Rituximab infusion precedes administration of the radiolabled immunoglobulin in order to occupy the abundant CD 20 binding sites on circulating and splenic B-cells. Although somewhat counter-intuitive, tumor uptake of the radiolabeled form of the antibody is actually greater when non-radiolabeled immunoglobulin is infused prior to the infusion of the radiolabeled form. Initially, clinical studies involved the infusion of an Indium-111 labeled ibritumomab preceded by a rituxin infusion in order to obtain dosimetry data and confirm biodistribution of the radiolabeled immunoglobulin (Figure 1) . Currently, within both the European and United States communities, use of the Indium-labeled form of the immunoglobulin followed by imaging is not required. Nevertheless, since the initial clinical trials involved the infusion of a potentially therapeutic amount of rituxin [450 mg/m 2 ], the entire regimen still consists of the initial infusion of rituximab alone followed one week later by a repeat infusion of rituximab followed by 90 Y-ibritumomab (15 MBq/kg if platelets are 150k/uL; 11 MBq/kg if platelets are >100k/ uL, <150mm 2 ; maximum dose 4.44GBq). In the initial efficacy trials comparing rituximab to Zevalin® in patients with indolent low grade lymphoma who had relapsed after chemotherapy, the Zevalin® regimen had an overall response rate [ORR] of 82% compared to rituximab alone which had an ORR of 33% with no Complete Responses [CR], By contrast, the Zevalin® treated group had 26% CR (2). In a subsequent randomized trial comparing Zevalin® to rituximab in patients who had relapsed or been refractory to chemotherapy but were rituximab naïve, , Zevalin® had an 89% ORR compared to a 56% ORR in patients receiving only rituximab alone. Zevalin® had a 30% CR compared to 16% for rituximab (3) . In general, patients with a CR have a longer PFS than patients only achieving a PR. The initial indication for use of Zevalin®, however, was in patients who had failed to respond to chemotherapy with rituximab or who had relapsed after responding to this regimen (Figure 2) . More recently, it has been demonstrated that the use of Zevalin® in patients who did respond, that is they achieved a CR or PR following traditional chemotherapy such as CHOP, CHOP-R, CVP, CVP-R, or fludarabine, increases the median PFS three-fold (36 months vs 13 months). In patients achieving a CR, the median PFS in the group who received Zevalin® was 54 months (4). The principal toxicity of Zevalin® therapy is hematologic with reduction of platelet count being the greatest concern. Patients should be monitored with complete blood and platelet counts weekly after infusion. In general, the platelets nadir from 4-7 weeks and generally return to about 80% of the ptre-therapy level. Many patients can be managed with observation alone but platelet infusions may become necessary. The absolute neutrophil count also may decline to 1000 cells/mm 2 .
SUMMARY AND CONCLUSIONS
In general, clinical responses [CR; PR] with RIT used after relapse are greater, and of greater duration, than alternative or repeat chemotherapies.
• RIT is safe and effective even after multiple relapses following chemotherapy and/or rituximab [Rituxin®] therapy. • The CR and ORR are even better when used as 1st line treatment in conjunction with chemotherapy or as "Consolidation" therapy.
• The principle toxicity of RIT of Zevalin® is hematologic; secondary to bone marrow irradiation from labeled antibody in blood and specific deposition on tumor cells in the bone marrow. • Patients should be followed with weekly CBC and Platelet Count: supportive measures such as growth factors &/or transfusions may be required but serious consequences are rare. • In the event of relapse (disease recurrence) after radioimmunotherapy, patients tolerate subsequent therapy as well or better than equivalent patients who have not received Radio Immuno Therapy.
• Radiation exposure of family members and health care personnel is low.
